JP2018529321A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529321A5
JP2018529321A5 JP2018506297A JP2018506297A JP2018529321A5 JP 2018529321 A5 JP2018529321 A5 JP 2018529321A5 JP 2018506297 A JP2018506297 A JP 2018506297A JP 2018506297 A JP2018506297 A JP 2018506297A JP 2018529321 A5 JP2018529321 A5 JP 2018529321A5
Authority
JP
Japan
Prior art keywords
protein
seq
amino acid
amino
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506297A
Other languages
English (en)
Japanese (ja)
Other versions
JP7008014B2 (ja
JP2018529321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/001344 external-priority patent/WO2017025179A1/en
Publication of JP2018529321A publication Critical patent/JP2018529321A/ja
Publication of JP2018529321A5 publication Critical patent/JP2018529321A5/ja
Application granted granted Critical
Publication of JP7008014B2 publication Critical patent/JP7008014B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506297A 2015-08-07 2016-08-04 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ Expired - Fee Related JP7008014B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180278 2015-08-07
EP15180278.2 2015-08-07
PCT/EP2016/001344 WO2017025179A1 (en) 2015-08-07 2016-08-04 A transglutamine tag for efficient site-specific bioconjugation

Publications (3)

Publication Number Publication Date
JP2018529321A JP2018529321A (ja) 2018-10-11
JP2018529321A5 true JP2018529321A5 (enExample) 2019-09-12
JP7008014B2 JP7008014B2 (ja) 2022-02-10

Family

ID=53785570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506297A Expired - Fee Related JP7008014B2 (ja) 2015-08-07 2016-08-04 有効な部位特異的バイオコンジュゲーションのためのトランスグルタミンタグ

Country Status (9)

Country Link
US (1) US11130818B2 (enExample)
EP (1) EP3331904B1 (enExample)
JP (1) JP7008014B2 (enExample)
CN (1) CN107922479A (enExample)
AU (1) AU2016306907A1 (enExample)
CA (1) CA2994741A1 (enExample)
ES (1) ES2855998T3 (enExample)
IL (1) IL256810B (enExample)
WO (1) WO2017025179A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP3272864A1 (en) * 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
DK3886914T3 (da) * 2018-11-30 2023-07-03 Bristol Myers Squibb Co Antistof omfattende en glutaminholdig letkæde-c-terminal forlængelse, konjugater deraf og fremgangsmåder samt anvendelser
CN113613679A (zh) 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
PT3865155T (pt) * 2020-02-13 2023-01-02 Orano Med Processo para modificação específica de local de um anticorpo
EP4213886A1 (en) 2020-09-18 2023-07-26 Araris Biotech AG Transglutaminase conjugation method with amino acid-based linkers
JP7789396B2 (ja) 2020-10-25 2025-12-22 アラリス バイオテック アーゲー 抗体-リンカーコンジュゲートを生成するための手段および方法
EP4422695A1 (en) 2021-10-25 2024-09-04 Araris Biotech AG Methods for producing antibody-linker conjugates
WO2023156849A2 (en) * 2022-02-17 2023-08-24 Revolo Biotherapeutics Limited Method of producing peptide derived from chaperonin 60.1
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
WO2025026338A1 (zh) * 2023-07-31 2025-02-06 石药集团巨石生物制药有限公司 具有高药物负载的抗体-药物缀合物及其用途
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
EP2033662B1 (en) * 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
JP6865584B2 (ja) 2013-12-23 2021-04-28 コヴァラブ 化合物の共有結合性コンジュゲーションのためのmTG基質
EP4032902A1 (en) * 2015-12-18 2022-07-27 Eisai R&D Management Co., Ltd. C-terminal lysine conjugated immunoglobulins

Similar Documents

Publication Publication Date Title
CL2019001000A1 (es) Proteínas de fusión fc heterodiméricas il15/il15ralfa
JP2019535315A5 (enExample)
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
IL261432B1 (en) Induced binding proteins and methods of use
PE20210844A1 (es) Contorsbodies 2 + biespecificos
JP2018033454A5 (enExample)
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
JP2020124209A5 (enExample)
JP2014158485A5 (enExample)
PE20211055A1 (es) Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
JP2019500862A5 (enExample)
AR066885A1 (es) Proteinas de fusion natriureticas
PE20212205A1 (es) Proteinas de union condicionalmente activadas restringidas
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
EA201200548A1 (ru) Биспецифические связывающие молекулы для антиангиогенезной терапии
JP2018537415A5 (enExample)
JP2016519932A5 (enExample)
EA201691780A1 (ru) Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения
JP2016514463A5 (enExample)
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
WO2009007244A3 (en) Replication deficient influenza virus for the expression of heterologous sequences
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
JP2012025766A5 (enExample)
JP2012025737A5 (enExample)